These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31315446)

  • 21. Implementation research: a protocol for two three-arm pragmatic randomised controlled trials on continuous glucose monitoring devices in people with type 1 diabetes in South Africa and Kenya.
    Marbán-Castro E; Muhwava L; Kamau Y; Safary E; Rheeder P; Karsas M; Kemp T; Freitas J; Carrihill M; Dave J; Katambo D; Kimetto J; Allie R; ; ; Ndungu J; Sigwebela N; Akach D; Girdwood S; Erkosar B; Nichols BE; Haldane C; Vetter B; Shilton S
    Trials; 2024 May; 25(1):331. PubMed ID: 38773658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of insulin regimen and glucose outcomes with short-term real-time continuous glucose monitoring (RT-CGM) in type 1 diabetic children with sub-optimal glucose control on multiple daily injections: The pediatric DIACCOR study.
    Picard S; Bonnemaison-Gilbert E; Leutenegger E; Barat P
    Arch Pediatr; 2019 Feb; 26(2):95-101. PubMed ID: 30642746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes.
    Sawyer A; Sobczak M; Forlenza GP; Alonso GT
    Diabetes Technol Ther; 2022 Jun; 24(6):409-415. PubMed ID: 35099306
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale.
    de Portu S; Vorrink L; Re R; Shin J; Castaneda J; Habteab A; Cohen O
    BMJ Open; 2022 Feb; 12(2):e050635. PubMed ID: 35110310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study).
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Pehrsson NG; Moström P
    J Diabetes Sci Technol; 2016 May; 10(3):754-61. PubMed ID: 27081191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures.
    Thomas MG; Avari P; Godsland IF; Lett AM; Reddy M; Oliver N
    Diabetes Obes Metab; 2021 Nov; 23(11):2521-2528. PubMed ID: 34286892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of telemedicine assessment on glycemic variability in children with type 1 diabetes mellitus.
    Peña NV; Torres M; Cardona JA; Iniesta R
    Diabetes Technol Ther; 2013 Feb; 15(2):136-42. PubMed ID: 23289433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.
    Raccah D; Sulmont V; Reznik Y; Guerci B; Renard E; Hanaire H; Jeandidier N; Nicolino M
    Diabetes Care; 2009 Dec; 32(12):2245-50. PubMed ID: 19767384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin Pump and CGM Usage in the United States and Germany: Results of a Real-World Survey With 985 Subjects.
    Walsh J; Roberts R; Weber D; Faber-Heinemann G; Heinemann L
    J Diabetes Sci Technol; 2015 Jun; 9(5):1103-10. PubMed ID: 26071425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the inter-subject variability in the relationship between glucose monitoring metrics and glycated hemoglobin for pediatric patients with type 1 diabetes.
    Bosoni P; Calcaterra V; Tibollo V; Malovini A; Zuccotti G; Mameli C; Sacchi L; Bellazzi R; Larizza C
    J Pediatr Endocrinol Metab; 2021 May; 34(5):619-625. PubMed ID: 33823102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of Insulin Regimen and Glucose Outcomes with Short-Term Real-Time Continuous Glucose Monitoring in Adult Type 1 Diabetes Patients with Suboptimal Control on Multiple Daily Injections: The Adult DIACCOR Study.
    Picard S; Hanaire H; Reznik Y; Benhamou PY; Fendri S; Dufaitre L; Leutenegger E; Guerci B
    Diabetes Technol Ther; 2018 Jun; 20(6):403-412. PubMed ID: 29847735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study.
    Petersson J; Åkesson K; Sundberg F; Särnblad S
    Pediatr Diabetes; 2019 May; 20(3):339-344. PubMed ID: 30652407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.
    Pratley RE; Kanapka LG; Rickels MR; Ahmann A; Aleppo G; Beck R; Bhargava A; Bode BW; Carlson A; Chaytor NS; Fox DS; Goland R; Hirsch IB; Kruger D; Kudva YC; Levy C; McGill JB; Peters A; Philipson L; Philis-Tsimikas A; Pop-Busui R; Shah VN; Thompson M; Vendrame F; Verdejo A; Weinstock RS; Young L; Miller KM;
    JAMA; 2020 Jun; 323(23):2397-2406. PubMed ID: 32543682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial.
    Lawson ML; Verbeeten KC; Courtney JM; Bradley BJ; McAssey K; Clarson C; Kirsch S; Curtis JR; Mahmud FH; Richardson C; Cooper T; Chan J; Tang K
    Pediatr Diabetes; 2021 Mar; 22(2):279-287. PubMed ID: 33098212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy.
    ; Weinzimer S; Xing D; Tansey M; Fiallo-Scharer R; Mauras N; Wysocki T; Beck R; Tamborlane W; Ruedy K
    Pediatr Diabetes; 2009 Apr; 10(2):91-6. PubMed ID: 19175899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.
    Mulinacci G; Alonso GT; Snell-Bergeon JK; Shah VN
    Diabetes Technol Ther; 2019 Jan; 21(1):6-10. PubMed ID: 30575413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world outcomes with different technology modalities in type 1 diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes.
    Diabetes Research in Children Network (DirecNet) Study Group
    Pediatr Diabetes; 2006 Feb; 7(1):32-8. PubMed ID: 16489972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.